Bluestar Genomics v. Song

CourtDistrict Court, N.D. California
DecidedDecember 21, 2023
Docket4:21-cv-04507
StatusUnknown

This text of Bluestar Genomics v. Song (Bluestar Genomics v. Song) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bluestar Genomics v. Song, (N.D. Cal. 2023).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 BLUESTAR GENOMICS, Case No. 21-cv-04507-JST

8 Plaintiff, ORDER GRANTING IN PART AND 9 v. DENYING IN PART DEFENDANT’S MOTION FOR JUDGMENT ON THE 10 CHUNXIAO SONG, et al., PLEADINGS 11 Defendants. Re: ECF No. 119

12 13 Before the Court is Defendant Dr. Chunxiao Song’s motion for judgment on the pleadings 14 and motion to stay. ECF No. 119. The Court will grant the motion as to Plaintiff Bluestar 15 Genomics’ (“Bluestar”) conversion claim; deny the motion in all other respects; and deny the 16 motion to stay as moot. 17 I. BACKGROUND 18 The Court’s prior order on Defendants’ motion to dismiss provides a comprehensive 19 factual and procedural background of this case. ECF No. 100. Here, the Court briefly summarizes 20 the relevant facts for the purposes of resolving the instant motion. 21 Bluestar and Dr. Song executed a contract for consulting services on October 1, 2016 22 (“Consulting Agreement”). On June 11, 2021, Bluestar brought claims against Dr. Song and the 23 Ludwig Institute for Cancer Research (“Ludwig”) based on Dr. Song’s breach of the Consulting 24 Agreement. ECF Nos. 1, 1-9. After Bluestar and Ludwig moved to dismiss the claims for lack of 25 personal jurisdiction, ECF No. 34, the Court dismissed the claims as to Ludwig but found that Dr. 26 Song was subject to personal jurisdiction. ECF No. 100. 27 This dispute arises out of Dr. Song’s alleged breach of the Consulting Agreement. ECF 1 work per month to Bluestar in exchange for equity in the founding of Bluestar, and at least $5,000 2 per month in cash compensation. ECF No. 81 ¶ 29. Dr. Song also agreed to assign to Bluestar: 3 all right, title and interest in and to any work product created by [Dr. Song], or to which [Dr. Song] contributes, pursuant to this 4 agreement (the “Work Product”), including all copyrights, trademarks and other intellectual property rights contained therein. 5 ECF No. 81-9 at 2; see also ECF No. 81 ¶ 26. Dr. Song does not dispute the terms of the 6 Consulting Agreement, that he entered into the Consulting Agreement, or that Ludwig was not a 7 party to the Consulting Agreement. 8 While the Consulting Agreement was operative, Dr. Song developed two technologies that 9 facilitate the detection of cancer: the 5mC technology1 and the TAPS technique.2 ECF No. 81 10 ¶¶ 43, 48. Ludwig filed a patent application for the 5mc technology on or about September 11, 11 2018, and the patent was issued July 16, 2020 (U.S. Patent Publication 2020/0224190). Id. ¶ 42. 12 Dr. Song sought patent protection—i.e., two provisional unpublished patent applications—for the 13 TAPS technique on or about January 2018. Id. ¶ 47; ECF No. 130 at 20. The public patent filings 14 related to this work “first began publishing in the 2019 time frame,” and ultimately issued 15 November 26, 2020 (U.S. Patent Publication 2020/0370114). ECF No. 81 ¶ 47. 16 Defendant Dr. Song brings this motion for judgment on the pleadings alleging that Ludwig 17 is a necessary or indispensable party because Ludwig is “the ultimate assignee of the 5mc and 18 TAPS technologies,” and a decision on the merits in this case will impact Ludwig’s rights. ECF 19 No. 119 at 6; ECF No. 132 at 2. Dr. Song also seeks to dismiss Bluestar’s claim for conversion as 20 barred by the statute of limitations. ECF No. 119 at 22. 21 II. JURISDICTION 22 The Court has jurisdiction under 28 U.S.C. § 1332. 23 24 25

26 1 Labeling a modified form of cytosine called 5-methylcytosine (“5mC”) in cell-free DNA via sequencing. ECF No. 100 at 2. 27 1 III. LEGAL STANDARD 2 A. Motion for Judgment on the Pleadings 3 The Ninth Circuit has explained the relevant standard as follows:

4 Judgment on the pleadings is proper when there are no issues of material fact, and the moving party is entitled to judgment as a 5 matter of law. All allegations of fact by the party opposing the motion are accepted as true, and are construed in the light most 6 favorable to that party. As a result, a plaintiff is not entitled to judgment on the pleadings when the answer raises issues of fact that, 7 if proved, would defeat recovery. 8 Gen. Conf. Corp. of Seventh-Day Adventists v. Seventh-Day Adventist Congregational Church, 9 887 F.2d 228, 230 (9th Cir. 1989) (citations omitted); see also Chavez v. U.S., 683 F.3d 1102, 10 1108 (9th Cir. 2012). The analysis under Rule 12(c) for a motion for judgment on the pleadings is 11 “functionally identical” to the analysis under Rule 12(b)(6) for a motion to dismiss. Gregg v. 12 Hawaii, Dep’t of Safety, 870 F.3d 883, 886–87 (9th Cir. 2017) (internal citations omitted). “A 13 defense of failure to join a party indispensable under Rule 19 . . . may be made . . . by motion for 14 judgment on the pleadings.” Fed. R. Civ. P. 12(h)(2). 15 B. Joinder of Absent Party 16 Federal Rule of Civil Procedure 19 imposes a three-step inquiry to determine whether 17 dismissal for failure to join a necessary and indispensable party is appropriate: (1) whether the 18 absent party is necessary; (2) whether it is feasible to order that the absent party be joined; and (3) 19 if joinder is not feasible, whether the case can proceed without the absent party. Salt River Project 20 Agric. Imp. & Power Dist. v. Lee, 672 F.3d 1176, 1179 (9th Cir. 2012) (citing Fed. R. Civ. P. 19). 21 The Court must first evaluate whether the absent party is necessary under Rule 19(a). A 22 party is only necessary if: (A) in that party’s absence, the court cannot accord complete relief; or 23 (B) the party claims “an interest relating to the subject of the action” and is situated such that 24 disposing of the action may (i) impair or impede that party’s ability to protect the interest; or (ii) 25 leave an existing party subject to substantial risk of incurring inconsistent obligations. Fed. R. 26 Civ. P. 19(a). “There is no precise formula for determining whether a particular non-party should 27 be joined under Rule 19(a). The determination is heavily influenced by the facts and 1 2010). 2 Only if the court determines that a party is a required party does it proceed to the second 3 inquiry: whether joinder is feasible. Alto v. Black, 738 F.3d 1111, 1126 (9th Cir. 2013). 4 IV. DISCUSSION 5 Dr. Song argues that the Court should grant judgment on the pleadings because Bluestar’s 6 claim of conversion is time barred, and because Ludwig is a necessary and indispensable party to 7 this action. 8 A. Bluestar’s Conversion Claim is Barred by the Statute of Limitations 9 The statute of limitations for a claim of conversion in California is three years. Cal. Code 10 Civ. Proc. § 338(c)(1). The statute does not begin to run until all essential elements of the cause 11 of action have occurred. Bd. of Trs. of Leland Stanford Junior Univ. v. Roche Molecular Sys., 12 Inc., 583 F.3d 832, 846 (Fed. Cir. 2009) (“Bd. of Trs. of Leland Stanford”).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Filmtec Corporation v. Allied-Signal Inc., and Uop Inc.
939 F.2d 1568 (Federal Circuit, 1991)
Delano Farms Co. v. California Table Grape Commission
655 F.3d 1337 (Federal Circuit, 2011)
Jose Chavez v. James Ziglar
683 F.3d 1102 (Ninth Circuit, 2012)
Oasis West Realty v. Goldman
250 P.3d 1115 (California Supreme Court, 2011)
Delano Farms Co. v. California Table Grape Commission
623 F. Supp. 2d 1144 (E.D. California, 2009)
California Shoppers, Inc. v. Royal Globe Insurance Co.
175 Cal. App. 3d 1 (California Court of Appeal, 1985)
Careau & Co. v. Security Pacific Business Credit, Inc.
222 Cal. App. 3d 1371 (California Court of Appeal, 1990)
Slovensky v. Friedman
49 Cal. Rptr. 3d 60 (California Court of Appeal, 2006)
Central Tools, Inc. v. Mitutoyo Corp.
381 F. Supp. 2d 71 (D. Rhode Island, 2005)
Albert Alto v. Kenneth Salazar
738 F.3d 1111 (Ninth Circuit, 2013)
Ali v. Carnegie Institution of Washington
306 F.R.D. 20 (District of Columbia, 2014)
Alexandria Gregg v. Hawaii Dept. of Public Safety
870 F.3d 883 (Ninth Circuit, 2017)
Glock v. Howard & Wilson Colony Co.
55 P. 713 (California Supreme Court, 1898)
Nasseri v. Wells Fargo Bank, N.A.
147 F. Supp. 3d 937 (N.D. California, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Bluestar Genomics v. Song, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bluestar-genomics-v-song-cand-2023.